Latest Breaking News On - மறுசீரமைப்பு பலகை - Page 1 : comparemela.com
Tax agreement between Ogdensburg, SLC could bring substantial funding to local towns, villages
northcountrynow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from northcountrynow.com Daily Mail and Mail on Sunday newspapers.
Opinion: Retired Ogdensburg Asst Fire Chief remains confused, says city manager
northcountrynow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from northcountrynow.com Daily Mail and Mail on Sunday newspapers.
Monday, June 14, 2021 - 5:46 pm
BY JIMMY LAWTON
North Country This Week
OGDENSBURG – City Manager Stephen Jellie says the City of Ogdensburg will lose up to $1.5 million in sales tax revenue after the New York State Assembly failed to pass home rule legislation regarding sales tax distribution.
The city plans to begin collecting its own sales tax in 2020, but won’t be able to collect 2.5 percent of the tax generated there without state approval. Instead it will collect just 1.5 percent, that’s a difference of as much as $1.5 million, according to estimates.
“The City of Ogdensburg is disappointed that the NYS Assembly was not able to act on a bill authorizing the collection of an additional 1 percent sales tax to be collected beginning in 2022. We sincerely hope the Assembly will follow the action to approve this bill that was approved by the NYS Senate on Thursday evening. Ogdensburg Mayor Jeffrey M. Skelly and City Council are greatly appreciative
Darlene Soave Joins Cell Source s Board of Directors
News provided by
Share this article
Share this article
NEW YORK, April 1, 2021 /PRNewswire/ Cell Source, Inc. (OTC: CLCS) ( Cell Source or the Company ), is the world leader in Veto Cell based innovative immunotherapy and today announced that Darlene Soave has been appointed to the Company s Board of Directors, effective March 25, 2021. Veto Cells, in different mouse models, have shown that they have the potential to safely facilitate mismatched donor stem cell (e.g. bone marrow) transplants and organ transplants. In addition, in preclinical trials, Veto Cells have shown that they can durably treat malignant and non-malignant blood diseases through active immune response management.